Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Heart Valves01:16

Heart Valves

4.8K
The human heart is a complex organ with an intricate system of valves that regulate blood flow. There are two main types of valves: atrioventricular (AV) valves and semilunar valves.
The AV valves prevent the backflow of blood from the ventricles to the atria during ventricular contraction. These valves function with the assistance of the chordae tendineae and papillary muscles. When the ventricles are relaxed, the chordae tendineae are slack, allowing blood to flow from the atria into the...
4.8K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

14
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

10
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
10

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

mRNA-based MRI contrast agent for precise diagnosis of glioma and pseudoprogression.

Cell biomaterials·2026
Same author

AAV.hBAG3 Gene Therapy Improves Phenotype in a Valosin Containing Protein Mouse Model of Hereditary Inclusion Body Myositis.

Human gene therapy·2026
Same author

Redo-TAVR (TAV-in-TAV) Best Practices Part 1: Short-in-Short and Short-in-Tall - A Heart and Valve Collaboratory Document.

JACC. Cardiovascular interventions·2026
Same author

Redo-TAVR (TAV-in-TAV) Best Practices Part 2: Tall-in-Short and Tall-in-Tall - A Heart and Valve Collaboratory Document.

JACC. Cardiovascular interventions·2026
Same author

Repurposing the skin to heal the body: Tissue Nanotransfection (TNT) as a therapeutic platform.

Med-X·2026
Same author

Occurrence of Substituted <i>p</i>-Phenylenediamine Antioxidants and Their Quinone Derivatives in the Pearl River Estuary Water System, China.

Toxics·2026

Related Experiment Video

Updated: Jul 14, 2025

Flow Cytometric Analysis of Extracellular Vesicles from Cell-conditioned Media
08:32

Flow Cytometric Analysis of Extracellular Vesicles from Cell-conditioned Media

Published on: February 12, 2019

13.8K

Engineered Extracellular Vesicle-Based Therapies for Valvular Heart Disease.

Ana I Salazar-Puerta1, Mia Kordowski2, Tatiana Z Cuellar-Gaviria1

  • 1Department of Biomedical Engineering, The Ohio State University, Fontana Laboratories, 140 W. 19th Ave., Columbus, OH 43210 USA.

Cellular and Molecular Bioengineering
|October 9, 2023
PubMed
Summary

Engineered extracellular vesicles (EVs) deliver reprogramming factors to calcified aortic valves, successfully inducing anti-inflammatory macrophage-like cells. This novel nanocarrier approach offers a promising therapy for heart valve disease.

Keywords:
Aortic calcific stenosisDirect cell reprogrammingEngineered extracellular vesiclesInflammationNon-viral gene delivery

More Related Videos

Combining 3D-Printing and Electrospinning to Manufacture Biomimetic Heart Valve Leaflets
10:29

Combining 3D-Printing and Electrospinning to Manufacture Biomimetic Heart Valve Leaflets

Published on: March 23, 2022

4.4K
Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
08:50

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Published on: August 16, 2024

751

Related Experiment Videos

Last Updated: Jul 14, 2025

Flow Cytometric Analysis of Extracellular Vesicles from Cell-conditioned Media
08:32

Flow Cytometric Analysis of Extracellular Vesicles from Cell-conditioned Media

Published on: February 12, 2019

13.8K
Combining 3D-Printing and Electrospinning to Manufacture Biomimetic Heart Valve Leaflets
10:29

Combining 3D-Printing and Electrospinning to Manufacture Biomimetic Heart Valve Leaflets

Published on: March 23, 2022

4.4K
Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
08:50

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Published on: August 16, 2024

751

Area of Science:

  • Cardiovascular Research
  • Nanomedicine
  • Regenerative Medicine

Background:

  • Valvular heart disease, particularly calcific aortic stenosis (CAS), is a major health concern in aging populations.
  • Current treatments like valve replacement have limitations in long-term durability.
  • Novel strategies are needed to halt or reverse CAS progression.

Purpose of the Study:

  • To explore the potential of extracellular vesicles (EVs) as nanocarriers for delivering therapeutic payloads to diseased aortic valves.
  • To investigate the use of engineered EVs loaded with specific transcription factors to reduce inflammation and promote calcified tissue resorption.

Main Methods:

  • Engineered EVs were loaded with reprogramming myeloid transcription factors, CEBPA and Spi1.
  • The ability of these EVs to deliver genetic material and induce cell transdifferentiation was evaluated in patient-derived aortic valve tissue.
  • In vitro and ex vivo models were used to assess the induction of macrophage-like cells from endothelial cells.

Main Results:

  • Engineered EVs loaded with CEBPA and Spi1 were successfully derived from human dermal fibroblasts.
  • These EVs effectively transfected aortic valve cells, inducing the transdifferentiation of endothelial cells into anti-inflammatory macrophage-like cells.
  • Successful transdifferentiation was observed both in vitro and ex vivo.

Conclusions:

  • Engineered EVs show potential as a next-generation nanocarrier for targeting aberrant calcifications in heart valves.
  • This approach may offer a novel therapeutic option for high-risk patients unsuitable for valve replacement surgery.